Reported 1 day ago
Top Wall Street analysts have made significant moves in ratings, with Baird initiating coverage of ServiceTitan with an Outperform rating and a price target of $117, forecasting higher profitability as the company expands. Meanwhile, Viracta Therapeutics has been downgraded to Neutral from Buy by Rodman & Renshaw, lowering its price target from $3.50 to 25 cents after halting a key clinical trial.
Source: YAHOO